Sana Biotechnology (NASDAQ:SANA) Stock Rating Upgraded by TD Cowen

Sana Biotechnology (NASDAQ:SANA) was upgraded by research analysts at TD Cowen to a “strong-buy” rating in a report issued on Monday,Zacks.com reports.

Other equities research analysts have also issued reports about the company. Weiss Ratings upgraded Sana Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 23rd. Wall Street Zen lowered Sana Biotechnology from a “hold” rating to a “sell” rating in a research note on Monday, July 20th. Rodman & Renshaw assumed coverage on Sana Biotechnology in a report on Monday, May 11th. They set a “buy” rating and a $16.00 target price on the stock. Finally, Bank of America lowered their target price on Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.33.

Sana Biotechnology Stock Down 3.3%

NASDAQ:SANA opened at $3.78 on Monday. The firm has a market cap of $1.13 billion, a PE ratio of -4.97 and a beta of 2.16. Sana Biotechnology has a 12 month low of $2.61 and a 12 month high of $6.55. The company’s 50-day moving average price is $3.49 and its two-hundred day moving average price is $3.41.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.02. On average, research analysts expect that Sana Biotechnology will post -0.72 EPS for the current fiscal year.

Institutional Trading of Sana Biotechnology

Several institutional investors and hedge funds have recently added to or reduced their stakes in SANA. BlackRock Inc. bought a new position in shares of Sana Biotechnology in the 2nd quarter valued at about $58,196,000. Canada Pension Plan Investment Board bought a new stake in shares of Sana Biotechnology during the second quarter worth approximately $35,662,000. Bank of America Corp DE acquired a new position in Sana Biotechnology in the second quarter valued at approximately $20,062,000. Alphabet Inc. acquired a new position in Sana Biotechnology in the second quarter valued at approximately $9,816,000. Finally, Balyasny Asset Management L.P. bought a new position in Sana Biotechnology in the fourth quarter valued at approximately $6,834,000. 88.23% of the stock is owned by institutional investors.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.